An Evidence-Based Review of Vascular Endothelial Growth Factor Inhibition in Pediatric Retinal Diseases: Part 2. Coats’ Disease, Best Disease, and Uveitis With Childhood Neovascularization

2012 ◽  
Vol 50 (1) ◽  
pp. 11-19 ◽  
Author(s):  
Khurram M. Chaudhary ◽  
Mihai Mititelu ◽  
Ronni M. Lieberman
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Evidence Based ◽  
Retinal Diseases ◽  
Vascular Endothelial ◽  
Coats Disease ◽  
Endothelial Growth Factor ◽  
Best Disease

scholarly journals Vascular endothelial growth factor in Coats’ disease

2013 ◽  
Vol 92 (3) ◽  
pp. e225-e228 ◽  
Author(s):  
Qi Zhao ◽  
Xiao-Yan Peng ◽  
Feng-Hua Chen ◽  
Yong-Peng Zhang ◽  
Lian Wang ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Vascular Endothelial ◽  
Coats Disease ◽  
Endothelial Growth Factor

scholarly journals Updates in Retinal Diseases 2018

2018 ◽  
Vol 12 (1) ◽  
pp. 19
Author(s):  
Maurizio Battaglia Parodi ◽  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Early Diagnosis ◽  
Vision Loss ◽  
Choroidal Neovascularisation ◽  
Retinal Diseases ◽  
Vascular Endothelial ◽  
Expert Interview ◽  
The University ◽  
Endothelial Growth Factor

Choroidal neovascularisation (CNV) is a major cause of vision loss. For more than 10 years, intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs have been used in the treatment of CNV. While effective, this treatment strategy is limited by the injection burden. Most patients require multiple injections and response levels can vary. Early diagnosis and treatment of CNV can increase the success rate of treatment. There is, therefore, considerable interest in identifying biomarkers both to identify patients most likely to respond to treatment and to facilitate early detection of the condition. In an expert interview, Maurizio Battaglia Parodi of the University Vita-Salute Milan, Italy, discusses the latest advances in CNV.

scholarly journals Vitrectomy and External Drainage of Subretinal Fluid Containing High Concentration of Vascular Endothelial Growth Factor for Advanced Coats Disease

2021 ◽  
Author(s):  
Fukutaro Mano ◽  
Itsuka Matsushita ◽  
Hiroyuki Kondo ◽  
Shoko Utamura ◽  
Chiori Kondo ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Case Series ◽  
Subretinal Fluid ◽  
Multivariable Logistic Regression Analysis ◽  
Vascular Endothelial ◽  
High Concentration ◽  
External Drainage ◽  
Coats Disease ◽  
Endothelial Growth Factor

Abstract This study investigated the surgical outcomes of Coats disease and the role of external drainage (XD) of subretinal fluid (SRF). The study is a multicenter retrospective interventional case series of 26 consecutive eyes of 26 patients who underwent surgeries for advanced Coats disease with retinal detachment. Main outcomes measured were: 1) comparison of complete SRF resolution with or without XD, and 2) variables that were associated with functional postoperative best-corrected visual acuity (BCVA) defined as BCVA of 0.1 or better, 3) intraocular vascular endothelial growth factor (VEGF) levels. Complete SRF resolution was achieved in all 14 eyes in which XD had been performed and in 75% of 12 eyes in which XD had not been performed (P =.03). Multivariable logistic regression analysis revealed that initial BCVA was the only variable associated with functional postoperative BCVA (odds ratio 3.24, 95% CI 0.93–11.33; P =.04). Markedly elevated VEGF levels were noted in the SRF compared with those in the vitreous humor (49,760 ± 52,990 vs. 707 ± 611 pg/mL, P =.03). XD seems to provide better anatomical success than without XD in the treatment of advanced Coats disease as XD could effectively eliminate substantial amount of VEGF in the SRF.

scholarly journals Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Shivi Agrawal ◽  
Malav Joshi ◽  
John B. Christoforidis
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Safety Profile ◽  
Intravitreal Injections ◽  
Retinal Diseases ◽  
Vascular Endothelial ◽  
Vital Importance ◽  
Anti Vegf ◽  
Endothelial Growth Factor ◽  
Ocular Safety

Vascular endothelial growth factor (VEGF) is a potent promoter of angiogenesis involved in a wide variety of physiologic processes. Intravitreal injections targeting VEGF have transformed the treatment of neovascular retinal diseases. Currently, there are four anti-VEGF agents in use: bevacizumab, ranibizumab, pegaptanib, and aflibercept. The success and frequency of anti-VEGF therapy have made the ocular safety profile of these agents of vital importance. This paper focuses on sterile endophthalmitis. In this paper, we compare the incidences of posttreatment sterile endophthalmitis among the four agents, review the mechanism of actions, and discuss the most prevalent hypotheses leading to sterile endophthalmitis.

Opportunities and Challenges in Translational Research: The Development of Photodynamic Therapy and Anti-Vascular Endothelial Growth Factor Drugs

2021 ◽  
Vol 49 (1) ◽  
pp. 19-24 ◽  
Author(s):  
Christina Kaiser Marko ◽  
Joan W. Miller
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Photodynamic Therapy ◽  
Growth Factor ◽  
Age Related Macular Degeneration ◽  
Retinal Diseases ◽  
Vascular Endothelial ◽  
Pharmacological Treatments ◽  
Age Related ◽  
Wide Range ◽  
Endothelial Growth Factor

AbstractThe development of photodynamic therapy and anti-vascular endothelial growth factor agents have revolutionized the treatment of retinal diseases, transforming the retina subspecialty by ushering in an age of pharmacological treatments for a wide range of diseases, including age-related macular degeneration (AMD).

scholarly journals Vitrectomy and external drainage of subretinal fluid containing high concentration of vascular endothelial growth factor for advanced coats disease

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Fukutaro Mano ◽  
Itsuka Matsushita ◽  
Hiroyuki Kondo ◽  
Shoko Utamura ◽  
Chiori Kondo ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Case Series ◽  
Subretinal Fluid ◽  
Multivariable Logistic Regression Analysis ◽  
Vascular Endothelial ◽  
High Concentration ◽  
External Drainage ◽  
Coats Disease ◽  
Endothelial Growth Factor

AbstractThis study investigated the surgical outcomes of Coats disease and the role of external drainage (XD) of subretinal fluid (SRF). The study is a multicenter retrospective interventional case series of 26 consecutive eyes of 26 patients who underwent surgeries for advanced Coats disease with retinal detachment. Main outcomes measured were: 1) comparison of complete SRF resolution with or without XD, and 2) variables that were associated with functional postoperative best-corrected visual acuity (BCVA) defined as BCVA of 0.1 or better, 3) intraocular vascular endothelial growth factor (VEGF) levels. Complete SRF resolution was achieved in all 14 eyes in which XD had been performed and in 75% of 12 eyes in which XD had not been performed (P = .03). Multivariable logistic regression analysis revealed that initial BCVA was the only variable associated with functional postoperative BCVA (odds ratio 3.24, 95% CI 0.93–11.33; P = .04). Markedly elevated VEGF levels were noted in the SRF compared with those in the vitreous humor (49,760 ± 52,990 vs. 707 ± 611 pg/mL, P = .03). XD seems to provide better anatomical success than without XD in the treatment of advanced Coats disease as XD could effectively eliminate substantial amount of VEGF in the SRF.

Sign in / Sign up

Export Citation Format

Share Document